1. Home
  2. DHIL vs KMDA Comparison

DHIL vs KMDA Comparison

Compare DHIL & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diamond Hill Investment Group Inc.

DHIL

Diamond Hill Investment Group Inc.

HOLD

Current Price

$172.61

Market Cap

463.8M

Sector

Finance

ML Signal

HOLD

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$8.92

Market Cap

458.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DHIL
KMDA
Founded
1990
1990
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.8M
458.6M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
DHIL
KMDA
Price
$172.61
$8.92
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$13.00
AVG Volume (30 Days)
21.4K
65.5K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
3.48%
2.21%
EPS Growth
14.37
N/A
EPS
17.91
N/A
Revenue
$145,201,729.00
N/A
Revenue This Year
N/A
$14.79
Revenue Next Year
N/A
$11.38
P/E Ratio
$9.61
$24.59
Revenue Growth
6.69
N/A
52 Week Low
$114.11
$5.54
52 Week High
$173.00
$9.35

Technical Indicators

Market Signals
Indicator
DHIL
KMDA
Relative Strength Index (RSI) 65.89 56.02
Support Level $170.59 $6.69
Resistance Level N/A $9.35
Average True Range (ATR) 0.69 0.27
MACD -0.19 -0.02
Stochastic Oscillator 68.88 60.00

Price Performance

Historical Comparison
DHIL
KMDA

About DHIL Diamond Hill Investment Group Inc.

Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Share on Social Networks: